To the Future, to the New Dorra pharma attends the 88th China International Pharmaceutical API/Intermediates/Packaging/Equipment Trade Fair

發(fā)布時(shí)間： 2023-04-18 閱讀：1272次

分享

From April 12th to 14th, the 88th China International Pharmaceutical API/Intermediates/Packaging/Equipment Trade Fair (API China) was held successfully in Qingdao Expo City International Exhibition Center.  The Dorra team was invited to the Exhibition to engage in-depth conversations with thousands of domestic pharmaceutical companies to jointly pursue development.

As the first professional Exhibition in the field of Chinese pharmaceutical industry in 2023, the Qingdao API Exhibition has narrowed the distance between domestic and overseas upstream and downstream pharmaceutical peers. The company's exhibitors have had enthusiastic discussions with new and old customers, seeking business opportunities, and laying a solid foundation for further cooperation.

At the same time, the first China Pharmaceutical Industry high quality development conference was held in the form of a main forum+several sub-forums, covered the development trend of the pharmaceutical industry, new drug research and development and improvement, pharmaceutical engineering and clean, green and environmental protection and other hot topics in the industry. The theme of the conference is "A New Path to the future", focusing on the future development of the industry and the opportunities in change, jointly discussing the current innovation and development opportunities and challenges faced by China's pharmaceutical industry, promoting the high-quality development of China's pharmaceutical industry, and contributing to the comprehensive promotion of the construction of a healthy China!

Taking this exhibition as an opportunity, leverage the advantages of an integrated industrial platform for R&D, production, and sales, Dorra Pharma will continue to devote ourselves completely to technology innovation and brand build and make every effort to foster the core competence for the company, and contribute to the construction of the development of China's pharmaceutical industry.